Rhythm Pharmaceuticals (RYTM) Assets Average (2017 - 2026)

Rhythm Pharmaceuticals (RYTM) has 10 years of Assets Average data on file, last reported at $461.3 million in Q1 2026.

• Assets Average for Q1 2026 came in at $461.3 million, up 18.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $461.3 million (up 18.43% YoY), and the FY2025 annual result was $436.2 million, up 20.34% from the prior year.
• Assets Average declined to $461.3 million in Q1 2026 per RYTM's latest filing, from $493.5 million in the prior quarter.
• Over five years, Assets Average peaked at $493.5 million in Q4 2025 and troughed at $281.2 million in Q2 2022.
• A 5-year average of $365.1 million and a median of $364.1 million in 2023 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2025: Assets Average slumped 30.61% in 2022, then surged 31.72% in 2025.
• A 5-year view of Assets Average shows it stood at $386.0 million in 2022, then retreated by 11.03% to $343.5 million in 2023, then rose by 10.03% to $377.9 million in 2024, then surged by 30.59% to $493.5 million in 2025, then slipped by 6.54% to $461.3 million in 2026.
• Business Quant data shows RYTM's Assets Average at $461.3 million in Q1 2026, $493.5 million in Q4 2025, and $439.8 million in Q3 2025.